Chicago Partners Investment Group’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$734K Buy
10,408
+3,844
+59% +$256K 0.01% 793
2026
Q1
$416K Buy
6,564
+137
+2% +$9.54K 0.01% 984
2025
Q4
$468K Buy
+6,427
New +$416K 0.01% 807
2022
Q2
Sell
-2,824
Closed -$218K 599
2022
Q1
$218K Sell
2,824
-96
-3% -$10.5K 0.02% 494
2021
Q4
$297K Buy
2,920
+100
+4% +$14.4K 0.02% 441
2021
Q3
$449K Buy
2,820
+92
+3% +$11.6K 0.03% 356
2021
Q2
$309K Sell
2,728
-296
-10% -$28.4K 0.02% 415
2021
Q1
$317K Sell
3,024
-96
-3% -$9.01K 0.03% 386
2020
Q4
$289K Buy
3,120
+96
+3% +$8.57K 0.03% 372
2020
Q3
$251K Sell
3,024
-184
-6% -$19.2K 0.03% 345
2020
Q2
$340K Buy
3,208
+460
+17% +$41.1K 0.04% 270
2020
Q1
$222K Buy
+2,748
New +$171K 0.03% 308

Other funds holding DXCM

Chicago Partners Investment Group's DXCM Position: Q2 2026 in Review

Chicago Partners Investment Group increased its DexCom (DXCM) stake by 59% in Q2 2026, buying an estimated $256K and bringing the position to 10,408 shares worth $734K. The position accounts for 0.01% of the portfolio, ranked #793.

Chicago Partners Investment Group first reported a position in DXCM in Q1 2020 and has held it in 12 quarters since. 968 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Chicago Partners Investment Group held 10,408 shares of DexCom worth $734K as of Q2 2026.
  • Chicago Partners Investment Group bought 3,844 DexCom shares in Q2 2026, an estimated $256K.
  • DexCom made up 0.01% of Chicago Partners Investment Group's portfolio in Q2 2026, its #793 holding.
  • Chicago Partners Investment Group first reported a position in DexCom in Q1 2020 and has held it in 12 quarters since.
  • 968 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Chicago Partners Investment Group's 13F filing for Q2 2026, filed 30 Jul 2026.